That is the big question. There are researchers who believe it does and there are researchers who say it doesn’t. Hard to know who to believe right? In a multicentered, blind, placebo-controlled, randomized trial conducted at 34 hospitals in the U.S., adults hospitalized with respiratory symptoms from severe acute respiratory syndrome coronavirus 2 infections were enrolled between April 2 and June 19, 2020. Patients were randomly assigned to hydroxychloroquine (400 mg twice daily for 2 doses, then 200 mg twice daily for 8 doses).
Among 479 patients who were randomized:
- Median age, 57 years,
- 20.1% in the intensive care unit,
- 46.8% receiving supplemental oxygen without positive pressure,
- 11.5% receiving non-invasive ventilation or nasal high-flow oxygen and
- 6.7% receiving invasive mechanical ventilation or extracorporeal membrane oxygenation.
Among adults hospitalized with respiratory illness from COVID-19, treatment with hydroxychloroquine, compared with placebo, did not significantly improve clinical status at day 14. These findings do not support the use of hydroxychloroquine for the treatment of COVID-19 among hospitalized adults. Again, there are other studies that differ, but the bottom line is, a vaccine is on the horizon and it can’t be available soon enough! Stay the course, stay strong, stay well, mask up, and stay tuned!